JÃ³zsÃ©f A TÃ¶zsÃ©r

List of Publications by Year
in descending order

148 papers	5,264 citations	87888 38 h-index	102487 66 g-index
148 all docs	148 docs citations	148 times ranked	6007 citing authors

#	Article	IF	Citations
1	Tobacco etch virus protease: mechanism of autolysis and rational design of stable mutants with wild-type catalytic proficiency. Protein Engineering, Design and Selection, 2001, 14, 993-1000.	2.1	729
2	The P1â€² specificity of tobacco etch virus protease. Biochemical and Biophysical Research Communications, 2002, 294, 949-955.	2.1	331
3	Research Applications of Proteolytic Enzymes in Molecular Biology. Biomolecules, 2013, 3, 923-942.	4.0	171
4	Comparison of the HIV-1 and HIV-2 proteinases using oligopeptide substrates representing cleavage sites in Gag and Gag-Pol polyproteins. FEBS Letters, 1991, 281, 77-80.	2.8	164
5	Beta-lactam compounds as apparently uncompetitive inhibitors of HIV-1 protease. Bioorganic and Medicinal Chemistry Letters, 2005, 15, 3086-3090.	2.2	141
6	Aloe vera downregulates LPS-induced inflammatory cytokine production and expression of NLRP3 inflammasome in human macrophages. Molecular Immunology, 2013, 56, 471-479.	2.2	137
7	Efficient site-specific processing of fusion proteins by tobacco vein mottling virus protease in vivo and in vitro. Protein Expression and Purification, 2004, 38, 108-115.	1.3	125
8	Kinetic and modeling studies of S3-S3' subsites of HIV proteinases. Biochemistry, 1992, 31, 4793-4800.	2.5	113
9	Quantitative analysis of proteins in the tear fluid of patients with diabetic retinopathy. Journal of Proteomics, 2012, 75, 2196-2204.	2.4	113
10	Natural Compounds as Regulators of NLRP3 Inflammasome-Mediated IL-1Î²Production. Mediators of Inflammation, 2016, 2016, 1-16.	3.0	104
11	Changes in the Chemical Barrier Composition of Tears in Alzheimerâ€™s Disease Reveal Potential Tear Diagnostic Biomarkers. PLoS ONE, 2016, 11, e0158000.	2.5	94
12	Folded Monomer of HIV-1 Protease. Journal of Biological Chemistry, 2001, 276, 49110-49116.	3.4	85
13	Atomic resolution crystal structures of HIV-1 protease and mutants V82A and I84V with saquinavir. Proteins: Structure, Function and Bioinformatics, 2007, 67, 232-242.	2.6	84
14	Substitution of proline with pipecolic acid at the scissile bond converts a peptide substrate of HIV proteinase into a selective inhibitor. Biochemical and Biophysical Research Communications, 1990, 169, 310-314.	2.1	73
15	Analysis of the efficacy of HIV protease inhibitors against SARS-CoV-2â€²s main protease. Virology Journal, 2020, 17, 190.	3.4	73
16	Studies on the role of the S4substrate binding site of HIV proteinases. FEBS Letters, 1991, 279, 356-360.	2.8	71
17	Crystal structures of HIV protease V82A and L90M mutants reveal changes in the indinavir-binding site. FEBS Journal, 2004, 271, 1516-1524.	0.2	71
18	Molecular basis for substrate recognition and drug resistance from 1.1 to 1.6 A resolution crystal structures of HIV-1 protease mutants with substrate analogs. FEBS Journal, 2005, 272, 5265-5277.	4.7	71

#	Article	IF	Citations
19	Kinetic, Stability, and Structural Changes in High-resolution Crystal Structures of HIV-1 Protease with Drug-resistant Mutations L24I, I50V, and G73S. Journal of Molecular Biology, 2005, 354, 789-800.	4.2	68
20	HIV-I protease: Maturation, enzyme specificity, and drug resistance. Advances in Pharmacology, 2000, 49, 111-146.	2.0	67
21	Effect of sequence polymorphism and drug resistance on two HIV-1 Gag processing sites. FEBS Journal, 2002, 269, 4114-4120.	0.2	64
22	Structural and Kinetic Analysis of Caspase-3 Reveals Role for S5 Binding Site in Substrate Recognition. Journal of Molecular Biology, 2006, 360, 654-666.	4.2	62
23	Quantitative body fluid proteomics in medicine â€" A focus on minimal invasiveness. Journal of Proteomics, 2017, 153, 30-43.	2.4	62
24	Comparison of the substrate specificity of the human T-cell leukemia virus and human immunodeficiency virus proteinases. FEBS Journal, 2000, 267, 6287-6295.	0.2	59
25	Proteomics investigation of OSCC-specific salivary biomarkers in a Hungarian population highlights the importance of identification of population-tailored biomarkers. PLoS ONE, 2017, 12, e0177282.	2.5	54
26	Stabilization from Autoproteolysis and Kinetic Characterization of the Human T-cell Leukemia Virus Type 1 Proteinase. Journal of Biological Chemistry, 1999, 274, 6660-6666.	3.4	52
27	HIV-1 protease inhibitors: effects on HIV-2 replication and resistance. Trends in Pharmacological Sciences, 2008, 29, 42-49.	8.7	51
28	Molecular mechanism of the short-term cardiotoxicity caused by 2â€²,3â€²-dideoxycytidine (ddC): modulation of reactive oxygen species levels and ADP-ribosylation reactions. Biochemical Pharmacology, 1999, 58, 1915-1925.	4.4	47
29	Tear fluid proteomics multimarkers for diabetic retinopathy screening. BMC Ophthalmology, 2013, 13, 40.	1.4	47
30	Combining mutations in HIV-1 protease to understand mechanisms of resistance. Proteins: Structure, Function and Bioinformatics, 2002, 48, 107-116.	2.6	46
31	Effect of caspase cleavage-site phosphorylation on proteolysis. Biochemical Journal, 2003, 372, 137-143.	3.7	45
32	Narrow Substrate Specificity and Sensitivity toward Ligand-binding Site Mutations of Human T-cell Leukemia Virus Type 1 Protease. Journal of Biological Chemistry, 2004, 279, 27148-27157.	3.4	45
33	Potential Resistance of SARS-CoV-2 Main Protease (Mpro) against Protease Inhibitors: Lessons Learned from HIV-1 Protease. International Journal of Molecular Sciences, 2022, 23, 3507.	4.1	45
34	Clustering of Class I HLA Oligomers with CD8 and TCR: Three-Dimensional Models Based on Fluorescence Resonance Energy Transfer and Crystallographic Data. Journal of Immunology, 2001, 166, 5078-5086.	0.8	41
35	Comparative Studies on Retroviral Proteases: Substrate Specificity. Viruses, 2010, 2, 147-165.	3.3	41
36	Studies on the substrate specificity of the proteinase of equine infectious anemia virus using oligopeptide substrates. Biochemistry, 1993, 32, 3347-3353.	2.5	40

#	Article	IF	Citations
37	Comparison of the substrate specificity of two potyvirus proteases. FEBS Journal, 2005, 272, 514-523.	4.7	40
38	Potent New Antiviral Compound Shows Similar Inhibition and Structural Interactions with Drug Resistant Mutants and Wild Type HIV-1 Proteaseâ€. Journal of Medicinal Chemistry, 2007, 50, 4509-4515.	6.4	40
39	HIV Inhibitors: Problems and Reality. Annals of the New York Academy of Sciences, 2001, 946, 145-159.	3.8	39
40	Critical differences in HIVâ€1 and HIVâ€2 protease specificity for clinical inhibitors. Protein Science, 2012, 21, 339-350.	7.6	38
41	Effect of substrate residues on the P2' preference of retroviral proteinases. FEBS Journal, 1999, 264, 921-929.	0.2	37
42	Amino Acid Preferences for a Critical Substrate Binding Subsite of Retroviral Proteases in Type 1 Cleavage Sites. Journal of Virology, 2005, 79, 4213-4218.	3.4	37
43	Molecular Modeling of Nearly Full-Length ErbB2 Receptor. Biophysical Journal, 2005, 88, 1354-1363.	0.5	36
44	Studies on the Symmetry and Sequence Context Dependence of the HIV-1 Proteinase Specificity. Journal of Biological Chemistry, 1997, 272, 16807-16814.	3.4	35
45	Development of a microtiter plate fluorescent assay for inhibition studies on the HTLV-1 and HIV-1 proteinases. Journal of Virological Methods, 2004, 119, 87-93.	2.1	35
46	Combined Methods for Diabetic Retinopathy Screening, Using Retina Photographs and Tear Fluid Proteomics Biomarkers. Journal of Diabetes Research, 2015, 2015, 1-8.	2.3	35
47	Comparison of the effect of FK506 and cyclosporin A on virus production in H9 cells chronically and newly infected by HIV-1. Archives of Virology, 1999, 144, 2151-2160.	2.1	32
48	Diabetic retinopathy: Proteomic approaches to help the differential diagnosis and to understand the underlying molecular mechanisms. Journal of Proteomics, 2017, 150, 351-358.	2.4	32
49	Transforming Growth Factor-Î² Induced Protein, Î²IG-H3, is Present in Degraded Form and Altered Localization in Lattice Corneal Dystrophy Type I. Experimental Eye Research, 1998, 66, 739-745.	2.6	31
50	Proteolytic Events of HIV-1 Replication as Targets for Therapeutic Intervention. Current Pharmaceutical Design, 2003, 9, 1803-1815.	1.9	31
51	Comparative Studies on the Substrate Specificity of Avian Myeloblastosis Virus Proteinase and Lentiviral Proteinases. Journal of Biological Chemistry, 1996, 271, 6781-6788.	3.4	29
52	Structural determinants of tobacco vein mottling virus protease substrate specificity. Protein Science, 2010, 19, 2240-2251.	7.6	28
53	Determination of plasminogen activator activities in normal and pathological human tears. The significance of tear plasminogen activators in the inflammatory and traumatic lesions of the cornea and the conjunctiva. Acta Ophthalmologica, 1990, 68, 508-514.	1.1	27
54	A molecular model of the full-length human NOD-like receptor family CARD domain containing 5 (NLRC5) protein. BMC Bioinformatics, 2013, 14, 275.	2.6	27

#	Article	IF	Citations
55	Ragweed pollen extract intensifies lipopolysaccharideâ€induced priming of <scp>NLRP</scp>3 inflammasome in human macrophages. Immunology, 2013, 138, 392-401.	4.4	26
56	Constitutive and UV-B modulated transcription of Nod-like receptors and their functional partners in human corneal epithelial cells. Molecular Vision, 2008, 14, 1575-83.	1.1	25
57	Effect of inducible bone morphogenetic protein 2 expression on the osteogenic differentiation of dental pulp stem cells in vitro. Bone, 2020, 132, 115214.	2.9	24
58	Amino Acid Preferences of Retroviral Proteases for Amino-Terminal Positions in a Type 1 Cleavage Site. Journal of Virology, 2008, 82, 10111-10117.	3.4	23
59	Molecular cloning, overproduction, purification and biochemical characterization of the p39 nsp2 protease domains encoded by three alphaviruses. Protein Expression and Purification, 2009, 64, 89-97.	1.3	23
60	Different dynamics of NLRP3 inflammasome-mediated IL-1Î² production in GM-CSFâ€“ and M-CSFâ€“differentiated human macrophages. Journal of Leukocyte Biology, 2017, 101, 1335-1347.	3.3	23
61	Solid phase synthesis of the proteinase of bovine leukemia virus Comparison of its specificity to that of HIV-2 proteinase. FEBS Letters, 1992, 309, 389-393.	2.8	22
62	Differential temperature dependence of tobacco etch virus and rhinovirus 3C proteases. Analytical Biochemistry, 2013, 436, 142-144.	2.4	22
63	Identification of Host Cellular Protein Substrates of SARS-COV-2 Main Protease. International Journal of Molecular Sciences, 2020, 21, 9523.	4.1	22
64	Molecular model of equine infectious anemia virus proteinase and kinetic measurements for peptide substrates with single amino acid substitutions. Biochemistry, 1993, 32, 3354-3362.	2.5	21
65	Characterization of the murine leukemia virus protease and its comparison with the human immunodeficiency virus type 1 protease. Journal of General Virology, 2006, 87, 1321-1330.	2.9	20
66	The Protease of Human T-Cell Leukemia Virus Type-1 is a Potential Therapeutic Target. Current Pharmaceutical Design, 2007, 13, 1285-1294.	1.9	20
67	Activity of Tethered Human Immunodeficiency Virus 1 Protease Containing Mutations in the Flap Region of One Subunit. FEBS Journal, 1997, 244, 235-241.	0.2	19
68	Expression and characterization of human foamy virus proteinase. FEBS Letters, 1999, 462, 397-401.	2.8	19
69	Comparative analysis of cytokine profiles of glaucomatous tears and aqueous humour reveals potential biomarkers for trabeculectomy complications. FEBS Open Bio, 2019, 9, 1020-1028.	2.3	19
70	Salivary IL-6 mRNA is a Robust Biomarker in Oral Squamous Cell Carcinoma. Journal of Clinical Medicine, 2019, 8, 1958.	2.4	19
71	Plasminogen activator activity and plasminogen independent amidolytic activity in tear fluid from healthy persons and patients with anterior segment inflammation. Clinica Chimica Acta, 1989, 183, 323-331.	1.1	18
72	Improved Parameters for Generating Partial Charges: Correlation with Observed Dipole Moments. Journal of Molecular Modeling, 1999, 5, 143-152.	1.8	18

#	Article	IF	Citations
73	Salivary proteome profiling of oral squamous cell carcinoma in a Hungarian population. FEBS Open Bio, 2018, 8, 556-569.	2.3	18
74	Bovine leukemia virus protease: comparison with human T-lymphotropic virus and human immunodeficiency virus proteases. Journal of General Virology, 2007, 88, 2052-2063.	2.9	17
75	Plasminogen activator inhibitor in human tears after laser refractive surgery. Journal of Cataract and Refractive Surgery, 2008, 34, 897-901.	1.5	17
76	Cloning of the bovine leukemia virus proteinase in Escherichia coli and comparison of its specificity to that of human T-cell leukemia virus proteinase. BBA - Proteins and Proteomics, 2000, 1478, 1-8.	2.1	16
77	Synthesis of homologous peptides using fragment condensation: analogs of an HIV proteinase substrate. International Journal of Peptide and Protein Research, 1991, 38, 453-458.	0.1	16
78	Functional Study of the Retrotransposon-Derived Human PEG10 Protease. International Journal of Molecular Sciences, 2020, 21, 2424.	4.1	16
79	Defective binding of SPINK1 variants is an uncommon mechanism for impaired trypsin inhibition in chronic pancreatitis. Journal of Biological Chemistry, 2021, 296, 100343.	3.4	15
80	Effect of serine and tyrosine phosphorylation on retroviral proteinase substrates. FEBS Journal, 1999, 265, 423-429.	0.2	14
81	Human immunodeficiency virus type 1 capsid protein is a substrate of the retroviral proteinase while integrase is resistant toward proteolysis. Virology, 2003, 310, 16-23.	2.4	14
82	HIV-1 Protease Dimer Interface Mutations that Compensate for Viral Reverse Transcriptase Instability in Infectious Virions. Journal of Molecular Biology, 2007, 372, 369-381.	4.2	14
83	Expression of the murine leukemia virus protease in fusion with maltose-binding protein in Escherichia coli. Protein Expression and Purification, 2004, 35, 62-68.	1.3	13
84	C-terminal residues of mature human T-lymphotropic virus typeÂ1 protease are critical for dimerization and catalytic activity. Biochemical Journal, 2008, 416, 357-364.	3.7	13
85	Inhibition Profiling of Retroviral Protease Inhibitors Using an HIV-2 Modular System. Viruses, 2015, 7, 6152-6162.	3.3	13
86	Wound-Healing Markers Revealed by Proximity Extension Assay in Tears of Patients following Glaucoma Surgery. International Journal of Molecular Sciences, 2018, 19, 4096.	4.1	13
87	Stages of HIV Replication and Targets for Therapeutic Intervention. Current Topics in Medicinal Chemistry, 2003, 3, 1447-1457.	2.1	13
88	Plasminogen activator activity and inhibition in rabbit tears after photorefractive keratectomy. Experimental Eye Research, 2003, 77, 675-680.	2.6	12
89	Discovery and significance of new human T-lymphotropic viruses: HTLV-3 and HTLV-4. Expert Review of Anti-Infective Therapy, 2009, 7, 1235-1249.	4.4	12
90	Activity of linked HIV-1 proteinase dimers containing mutations in the active site region. Protein Engineering, Design and Selection, 1996, 9, 997-1003.	2.1	11

#	Article	IF	Citations
91	Urokinase-Type Plasminogen Activator to Prevent Haze after Photorefractive Keratectomy, and Pregnancy as a Risk Factor for Haze in Rabbits. Investigative Ophthalmology and Visual Science, 2004, 45, 1329-1333.	3.3	11
92	Synthesis, Processing, and Composition of the Virion-associated HTLV-1 Reverse Transcriptase. Journal of Biological Chemistry, 2006, 281, 3964-3971.	3.4	11
93	The substrate specificity of Metarhizium anisopliae and Bos taurus carboxypeptidases A: Insights into their use as tools for the removal of affinity tags. Protein Expression and Purification, 2011, 77, 53-61.	1.3	11
94	Urokinase-type plasminogen activator in rabbit tears. Comparison with human tears. Experimental Eye Research, 1990, 51, 33-37.	2.6	10
95	A recombinant fusion protein-based, fluorescent protease assay for high throughput-compatible substrate screening. Analytical Biochemistry, 2018, 540-541, 52-63.	2.4	10
96	Analysis of networks of host proteins in the early time points following HIV transduction. BMC Bioinformatics, 2019, 20, 398.	2.6	10
97	Dimer Interface Organization is a Main Determinant of Intermonomeric Interactions and Correlates with Evolutionary Relationships of Retroviral and Retroviral-Like Ddi1 and Ddi2 Proteases. International Journal of Molecular Sciences, 2020, 21, 1352.	4.1	10
98	Biochemical Characterization, Specificity and Inhibition Studies of HTLV-1, HTLV-2, and HTLV-3 Proteases. Life, 2021, 11, 127.	2.4	10
99	Proteomic analysis of protein phosphatase Z1 from Candida albicans. PLoS ONE, 2017, 12, e0183176.	2.5	10
100	Fast and Sensitive Quantification of AccQ-Tag Derivatized Amino Acids and Biogenic Amines by UHPLC-UV Analysis from Complex Biological Samples. Metabolites, 2022, 12, 272.	2.9	10
101	Metabolomic Analysis of Serum and Tear Samples from Patients with Obesity and Type 2 Diabetes Mellitus. International Journal of Molecular Sciences, 2022, 23, 4534.	4.1	10
102	NADP-specific glutamate dehydrogenase ofPenicillium chrysogenum has a homohexamer structure. Journal of Basic Microbiology, 1996, 36, 371-375.	3.3	9
103	Novel macromolecular inhibitors of human immunodeficiency virus-1 protease. Protein Engineering, Design and Selection, 2008, 21, 453-461.	2.1	9
104	Plasminogen activator inhibitors in human tears. Acta Ophthalmologica, 1991, 69, 426-431.	1.1	9
105	Enhanced Stability of Monomer Fold Correlates with Extreme Drug Resistance of HIV-1 Protease. Biochemistry, 2013, 52, 7678-7688.	2.5	9
106	Data supporting Ni-NTA magnetic bead-based fluorescent protease assay using recombinant fusion protein substrates. Data in Brief, 2018, 18, 203-208.	1.0	9
107	Biochemical characterization of Ty1 retrotransposon protease. PLoS ONE, 2020, 15, e0227062.	2.5	9
108	Compounds with Antiviral, Anti-Inflammatory and Anticancer Activity Identified in Wine from Hungaryâ€™s Tokaj Region via High Resolution Mass Spectrometry and Bioinformatics Analyses. International Journal of Molecular Sciences, 2020, 21, 9547.	4.1	9

#	Article	IF	Citations
109	Specificity of retroviral proteinases based on substrates containing tyrosine and proline at the site of cleavage. Pathology and Oncology Research, 1997, 3, 142-146.	1.9	8
110	Structural and biochemical characterization of the inhibitor complexes of xenotropic murine leukemia virusâ€related virus protease. FEBS Journal, 2011, 278, 4413-4424.	4.7	8
111	Inhibition of XMRV and HIVâ€1 proteases by pepstatin A and acetylâ€pepstatin. FEBS Journal, 2012, 279, 3276-3286.	4.7	8
112	The proteomic profile of a mouse model of proliferative vitreoretinopathy. FEBS Open Bio, 2017, 7, 1166-1177.	2.3	8
113	Regulation of calpain B from Drosophila melanogaster by phosphorylation. FEBS Journal, 2009, 276, 4959-4972.	4.7	7
114	Use of Recombinant Fusion Proteins in a Fluorescent Protease Assay Platform and Their In-gel Renaturation. Journal of Visualized Experiments, 2019, , .	0.3	7
115	Effect of Inducible BMP-7 Expression on the Osteogenic Differentiation of Human Dental Pulp Stem Cells. International Journal of Molecular Sciences, 2021, 22, 6182.	4.1	7
116	Development of a Bio-Layer Interferometry-Based Protease Assay Using HIV-1 Protease as a Model. Viruses, 2021, 13, 1183.	3.3	7
117	Lactate dehydrogenase activity in pathological human tears obtained with glass capillaries correlates with the albumin content. , 1998, 22, 289-292.		6
118	Effect of experimental hypercholesterolaemia on K+ channel Î±-subunit mRNA levels in rabbit hearts. European Journal of Pharmacology, 2007, 562, 130-131.	3.5	6
119	Relative quantification of human Î²â€defensins by a proteomics approach based on selected reaction monitoring. Rapid Communications in Mass Spectrometry, 2015, 29, 1623-1631.	1.5	6
120	Specificity Studies of the Venezuelan Equine Encephalitis Virus Non-Structural Protein 2 Protease Using Recombinant Fluorescent Substrates. International Journal of Molecular Sciences, 2020, 21, 7686.	4.1	6
121	Drug Targets in Human T-Lymphotropic Virus Type 1 (HTLV-1) Infection. Infectious Disorders - Drug Targets, 2009, 9, 159-171.	0.8	6
122	In Vitro Processing of HIV-1 Nucleocapsid Protein by the Viral Proteinase:â€‰ Effects of Amino Acid Substitutions at the Scissile Bond in the Proximal Zinc Finger Sequence. Biochemistry, 2004, 43, 4304-4312.	2.5	5
123	Improved purification protocol for wild-type and mutant human foamy virus proteases. Protein Expression and Purification, 2006, 46, 343-347.	1.3	5
124	Inhibitory Effects of HIV-2 Vpx on Replication of HIV-1. Journal of Virology, 2018, 92, .	3.4	5
125	A Modular System to Evaluate the Efficacy of Protease Inhibitors against HIV-2. PLoS ONE, 2014, 9, e113221.	2.5	5
126	Tear plasminogen activators ? indicators of epithelial cell destruction. The effect of scraping, n-heptanol debridement, and alkali burn of the cornea on the plasminogen activator activity of rabbit tears. International Ophthalmology, 1991, 15, 363-369.	1.4	4

#	Article	IF	Citations
127	Soluble cell-bound and extracellular cyclodextrin glycosyltransferases ofBacillus macerans show identical enzymological characteristics and antigenicity. Journal of Basic Microbiology, 1996, 36, 335-340.	3.3	4
128	Plasminogen activator activity in tears of pregnant women. PLoS ONE, 2017, 12, e0177003.	2.5	4
129	Biochemical Characterization of Human Retroviral-Like Aspartic Protease 1 (ASPRV1). Biomolecules, 2020, 10, 1004.	4.0	4
130	Examination of Oral Squamous Cell Carcinoma and Precancerous Lesions Using Proximity Extension Assay and Salivary RNA Quantification. Biomedicines, 2020, 8, 610.	3.2	4
131	Cellular Proteo-Transcriptomic Changes in the Immediate Early-Phase of Lentiviral Transduction. Microorganisms, 2021, 9, 2207.	3.6	4
132	Effect of mutations on the dimer stability and the pH optimum of the human foamy virus protease. Protein Engineering, Design and Selection, 2006, 19, 369-375.	2.1	3
133	HIV-1 Protease and AIDS Therapy. , 2009, , 25-45.		3
134	Replication-dependent fitness recovery of Human immunodeficiency virus 1 harbouring mutations of Asn17 of the nucleocapsid protein. Journal of General Virology, 2006, 87, 961-965.	2.9	2
135	Effect of internal cleavage site mutations in human immunodeficiency virus type 1 capsid protein on its structure and function. FEBS Open Bio, 2016, 6, 847-859.	2.3	2
136	Reduced Level of Tear Antimicrobial and Immunomodulatory Proteins as a Possible Reason for Higher Ocular Infections in Diabetic Patients. Pathogens, 2021, 10, 883.	2.8	2
137	Moloney murine leukemia virus retropepsin. , 2004, , 176-178.		2
138	Chemical Barrier Proteins in Human Body Fluids. Biomedicines, 2022, 10, 1472.	3.2	2
139	Urokinase Down-Regulation by Aprotinin in Rabbit Corneal Cells After Photorefractive Keratectomy. Current Eye Research, 2010, 35, 806-811.	1.5	1
140	Bovine Leukemia Virus Retropepsin. , 2013, , 218-220.		1
141	Specificity of the HIV-1 Protease on Substrates Representing the Cleavage Site in the Proximal Zinc-Finger of HIV-1 Nucleocapsid Protein. Viruses, 2021, 13, 1092.	3.3	1
142	Equine Infectious Anemia Virus Retropepsin. , 2013, , 207-210.		0
143	Mouse Mammary Tumor Virus Retropepsin. , 2013, , 223-226.		0
144	Moloney Murine Leukemia Virus Retropepsin. , 2013, , 226-230.		0

#	Article	IF	Citations
145	Study of the Retrotransposon-Derived Human PEG10 Protease. Proceedings (mdpi), 2020, 50, 110.	0.2	0
146	Y44A Mutation in the Acidic Domain of HIV-2 Tat Impairs Viral Reverse Transcription and LTR-Transactivation. International Journal of Molecular Sciences, 2020, 21, 5907.	4.1	0
147	Elucidating the Role of HIV-2 Viral Protein X. Proceedings (mdpi), 2020, 50, 24.	0.2	0
148	Equine infectious anemia virus retropepsin. , 2004, , 160-163.		0